GFR alpha-1

GFR alpha-1 Overview

English NameGlial cell line-derived neurotrophic factor receptorsApproved Drugs0
Drugs in Clinical Trials3Target SynonymGlial Cell Line-Derived Neurotrophic Factor Receptors
Highest Development StagePhase 2 Clinical
English NameGlial cell line-derived neurotrophic factor receptors
Target SynonymGlial Cell Line-Derived Neurotrophic Factor Receptors
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 2 Clinical

GFR alpha-1 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
GF1-H5224
Human
HEK293
Human GFR alpha-1 Protein, His Tag
Total: 1
  • 1

GFR alpha-1 Background

GDNF family receptor alpha-1 (GFRA1) is also known as RET ligand 1 (RETL1), TGF-beta-related neurotrophic factor receptor 1 (TRNR1), is a novel glycosylphosphatidylinositol (GPI)-linked cell surface receptor, and belongs to the glial cell line-derived neurotrophic factor (GDNF) receptor subfamily. The GDNF family ligands comprises GDNF, Neurturin (NTN), Artemin, and Persephin. GDNF and NTN are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation. GFRA1 mediates the association with and activation of the RET tyrosine kinase receptor (RTK), and subsequently initiates the RET signaling pathway. GFR alpha-mediated signaling plays an important role in the survival, differentiation, and migration of central and peripheral neurons, and is essential for the development of kidneys and the enteric nervous system, as well as the inflammatory response in some carciniomas.

GFR alpha-1 Synonyms

GFRA1,GDNFRA,RETL1,TRNR1,GDNFR,GFR-ALPHA-1,RET1L

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
KLS-2031KLS-2031Phase 2 ClinicalKolon Life Science. IncNeuralgia; Radiculopathy
Details
NGM-386NGM-386Phase 1 ClinicalNGM Biopharmaceuticals IncObesity
Details
NGM-395NGM-395Phase 1 ClinicalNGM Biopharmaceuticals IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland